Novartis U.S. pharmaceuticals head to be James Callahan of Ciba.
NOVARTIS U.S. PHARMACEUTICALS HEAD WILL BE CALLAHAN, the current head of Ciba's U.S. pharmaceuticals division, Ciba-Geigy and Sandoz announced May 7. James Callahan will report to Novartis worldwide health care division and pharmaceuticals sector head Pierre Douaze in Basel, Switzerland. The companies, which plan to merge when regulatory authorities have given approval, appointed positions for the merged U.S. operations of Novartis.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth